Ignite Creation Date:
2024-05-06 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05344976
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-04-25
First Post:
2022-04-19
Brief Title:
MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
An Exploratory Clinical Study on the Safety and Efficacy of MSLN STAR-T Cells in Advanced Malignant Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-center single-arm open-label Phase I study to evaluate the safety and efficacy of MSLN STAR-T cell immunotherapy in the treatment of advanced malignant solid tumors
Detailed Description:
This study is a single-center dose-escalation prospective exploratory study to evaluate the safety and efficacy of MSLN STAR-T cells in patients with hepatocellular carcinoma The study is divided into two phases dose escalation and dose expansion The total duration of each subjects participation in the study is expected to be 24 months including the screening period non-myeloablative chemotherapy pretreatment cell infusion-observation period and follow-up period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None